|
Ronald A. DePinho, M.D., president of The University of Texas MD Anderson Cancer Center in Houston, is internationally recognized for basic and translational research in cancer, aging and age-associated degenerative disorders. DePinho became president on Sept. 1, 2011.〔(【引用サイトリンク】title=Incoming MD Anderson chief sets challenge for institution )〕 He is only the fourth full-time president in the 70-year history of MD Anderson.〔(【引用サイトリンク】title=MD Anderson's Past Presidents )〕 Prior to joining MD Anderson, he spent 14 years at Dana-Farber Cancer Institute and Harvard Medical School in Boston. There, he was founding director of the Belfer Institute for Applied Cancer Science at Dana-Farber and was a professor in the Department of Medicine (genetics) at Harvard and an American Cancer Society Research Professor. Previously, he held numerous faculty positions during 10 years at Albert Einstein College of Medicine in New York. He currently has a salary of $1,845,000.〔(【引用サイトリンク】accessdate=July 21, 2014 )〕 ==Research== At Dana-Farber and Harvard, DePinho guided major basic-translational research programs focused on brain, colorectal, pancreatic and prostate cancers. Under his leadership, the Belfer Institute followed industry-like principles to systematically translate basic research findings into clinical endpoints. His scientific program has made fundamental discoveries underlying cancer in the aged and factors governing acquired and inherited degenerative disorders. He established the concept of tumor maintenance, discovered a core pathway of aging and demonstrated that aging is a reversible process.〔(【引用サイトリンク】title=Partial reversal of aging achieved in mice )〕 He has constructed and used refined mouse models of cancer to identify many new cancer targets and diagnostics. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Ronald A. DePinho」の詳細全文を読む スポンサード リンク
|